X-Therma hints at what’s next: a revolution in organ transplantation and preservation

X-Therma, a member of the Biotechnology Innovation Organization (BIO), recently announced significant strides towards changing the future of organ preservation and transportation. On March 13, the San Francisco-based company announced developments in its research pipeline and the finalization of Series B funding.

Xiaoxi Wei, Ph.D., Co-Founder and CEO of X-Therma, has made it her life’s mission to “uncover solutions to increase organ availability and to one day abolish the organ transplant list,” as she previously told Bio.News. Her journey began with the investigation of anti-freeze proteins (AFPs), whose resilience allowed a variety of aquatic species to survive at sub-zero temperatures. The evolving platform in place at X-Therma involves their own novel molecule, or “peptoid,” that was developed using biomimetic science.

The infusion of Series B funding will help drive the company towards global commercial operations and the progression into the clinical stage of R&D.

What’s in the X-Therma pipeline?

X-Therma’s breakthrough, non-toxic cryopreservation fluid, XT-Thrive, is poised to provide advanced cell recovery and functionality for life-saving regenerative modalities, such as vaccines, cell and gene therapies, and bioengineered tissues. XT-Thrive stands out as an alternative to standard cryopreservation agents, known for its ability to be a “plug and play” technology for cell and tissue manufacturing.